Solutions to reduce complications of prostatectomy

Levee Medical, Inc. is focused on developing innovative medical solutions aimed at improving recovery outcomes for patients undergoing radical prostatectomy, particularly addressing the issue of urinary incontinence, which is a common and distressing complication following prostate cancer surgery. Their flagship product, the Voro® Urologic Scaffold, is an absorbable device specifically designed to mitigate early urinary incontinence. This device is currently in the research and development phase and has not yet received FDA approval or clearance for sale. The company is committed to advancing clinical studies to establish the safety and efficacy of the Voro scaffold, with recent funding milestones supporting these efforts.

The company has made significant progress in its clinical development, including the successful enrollment of patients in its first-in-human study, which aims to gather initial safety data for the Voro Urologic Scaffold. Levee Medical has secured substantial investments to accelerate the development of this novel device, reflecting a strong commitment to enhancing surgical outcomes for prostate cancer patients. Their ongoing research and clinical activities are geared towards transforming the post-prostatectomy recovery experience, ultimately aiming to improve the quality of life for men affected by prostate cancer.

United States

Levee Medical, Inc. designs, develops, and manufactures innovative urological devices with the focus of improving recovery outcomes post-prostatectomy so that patients can quickly and confidently return to normal activity. The company's inaugural product is designed to support and stabilize the post-operative bladder neck and urethra following prostatectomy to accelerate the return of continence and reduce the overall risk of chronic incontinence.

Levee Medical, Inc.

Company Details